Dopamine D2 receptor Taq A1 allele predicts treatment compliance of LG839 in a subset analysis of pilot study in the Netherlands

Gene Therapy and Molecular Biology

Volumn 12, Issue 1, 2008, Pages 129-140

  Blum, Kenneth ^a,e,h   Chen, Thomas J H ^b   Chen, Amanda L C ^b   Rhoades, Patrick ^c   Prihoda, Thomas J ^d   Downs, B William ^e   Bagchi, Debasis ^f,g   Bagchi, Manashi ^f   Blum, Seth H ^h   Williams, Lonna ^e   Braverman, Eric R ⁱ   Kerner, Mallory ⁱ   Waite, Roger L ^e   Quirk, Brien ^j   White, Lisa ^k,m   Reinking, Jeffrey ^l  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^c Comphrehensive Obesity Clinic ^*  (United States)

^d University of Texas Health Science Center at San Antonio   (United States)

^e LifeGen Inc   (United States)

^f InterHealth Nutraceuticals Inc   (United States)

^g CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^h Synaptamine Inc   (United States)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

^j Draco Natural Products Inc   (United States)

^k BAYLOR COLLEGE OF MEDICINE   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m DNA Services of America   (United States)

more..

Author keywords

Aminoacids; Dopamine genetics; Drd2gene; LG839; Pharmacogenomics; Pharmcogenetics; Reward Deficiency Syndrome (RDS)

Indexed keywords

EID: 50849101695     PISSN: 15299120     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. American Heart Association, http://www.american.heart.org/ presenter.jhtml?identifier=10, Accessed July 11, 2007.
2. Bilkei-Gorzo A, Racz I, Michel K, Mauer D, Zimmer A, Klingmüller D, Zimmer A (2008) Control of hormonal stress reactivity by the endogenous opioid system. Psychoneuroendocrinology 33, 425-436
3. Blum K, Braverman ER (2000) Reward Deficiency Syndrome: A Biogenetic Model For the Diagnosis And Treatment Of Impulsive, Addictive and Compulsive Behaviors. J Psychoactive Drugs 32, 1-112 (Supplement).
4. Blum K, Chen TJ, Meshkin B, Downs BW, Gordon CA, Blum S, Mengucci JF, Braverman ER, Arcuri V, Varshavskiy M, Deutsch R, Martinez-Pons M ( 2006) Reward deficiency syndrome in obesity: a preliminary cross-sectional trial with a Genotrim variant. Adv Ther 23, 1040-1051.
5. Blum K, Chen TJH, Downs BW, Meshkin B, Blum SH, Martinez Pons M, Mengucci JF, Waite RL, Arcuri V, Varshofsiky M, Braverman ER (2007a) Synaptamine (SG8839)™: An Amino-Acid Enkephalinase Inhibition Nutraceutical Improves Recovery of Alcoholics, A Subtype of Reward Deficiency Syndrome (RDS). Trends in Applied Sciences Research 2, 132-138.
6. Blum K, Meshkin B, Prihoda TJ, Downs BW, Waite RL, Braverman ER, White L (2007b) DNA-Customized Genotrim® induces significant reductions in weight, appetite and sugar cravings in the D.I.E.T. study: Polymorphic correlates involving five candidate genes in Obesity, a clinical subtype of Reward Deficiency Syndrome (RDS). Presented at the Natural Products Association Meeting, July 21st Las Vegas, NV 2007 (abstract).
7. 2 receptor gene in alcoholism. JAMA 263,2055-2060.
8. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Cull JG, Comings DE. (1996) The D2 doparnine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med 89,396-400.
9. Blum, K. Elston Sf, Delallo I, Briggs, AH, Wallace JE (1983) Ethanol acceptance as a function of genotype amounts of brain [Met] enkephalin. Proc Natl Acad Sci U S A 80, 6510-6512.
10. Blum, K., and Kozlowski, GP (1990) Ethanol and neuromodulator interactions: a cascade model of reward. In: Ollat, H., Parvez, S. and Parvez, H (Eds), Alcohol and Behavior, Utrecht, Netherlands, VSP Press 131-149.
11. Buckalew LW, Sallos RE (1986) Patient compliance and medication perception. J Clin Psychol 42,49-53.
12. Catalan V, Gomez-Ambrosi J, Rotellar F, Silva C, Rodriguez A, Salvador J, Gil MJ, Cienfuegos JA, Frubbeck G. (2007) Validation of Endogenous Control Genes in Human Adipose Tissue: Relevance to Obesity and Obesity-associated Type 2 Diabetes Mellitus. Horm Metab Res. 39,495-500.
13. Chen TJ, Blum K, Payte JT, Schoolfield J, Hopper D, Stanford M, Braverman ER (2004) Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, arnino-acid precursors and enkephalinase inhibition therapy. Med Hypotheses. 63, 538-548.
14. Chen TJ, Blum K, Waite RL, Meshkin B, Schoolfield J, Downs BW, Braverman EE, Arcuri V, Varshavskiy M, Blum SH, Mengucci J, Reuben C, Palomo T ( 2007b) Gene narcotic attenuation program attenuates substance use disorder, a clinical subtype of reward deficiency syndrome. Adv Ther 24, 402-414.
15. Chen TJH, Blum K, Kaats G, Braverman E, Pullin D, Downs BW, Martinez-Pons M, Blum SH, Mengucci J, Bagchi d, Bagchi M, Robarge A, Meshkin B, Arcuri V, Varshavskiy M, Notaro A, Comings DF, White L ( 2007a) Reviewing the role of putative candidate genes in " Neurobesigenics," a clinical subtype of Reward Deficiency Syndrome (RDS). Gene Ther Mol Biol 11, 61-74.
16. Comings DE (1996) Genetic factors in drug abuse and dependence. NIDA Res Monogr 159, 16-38.
17. Comings DE, Gade R, MacMurray JP, Muhleman D, Peters WR (1996) Genetic variants of the human obesity gene: Association with psychiatric symptoms and body mass index in young women, and interaction with the dopamine D2 receptor gene. Mol Psychiatry 1, 325-335.
18. Connor JP, Young RM, Lawford BR, Ritchie TL, Noble EP (2002) D(2) dopamine receptor (DRD2) polymorphism is associated with severity of alcohol dependence. Eur Psychiatry 17, 17-23.
19. Davis C, Fox J (2008) Sensitivity to reward and body mass index (BMI): evidence for a non-linear relationship. Appetite 50, 43-9.
20. DoctorSolve Press Release, October 17, 2006, "Medication Noncompliance is Taking a Serious Toll on Patients' Health and the Healthcare System, says DoctorSolve." http://www.prweb.com/releases /2006/10/prweb450691.htm, Accessed on July 11, 2007.
21. Duaux E, Gorwood P, Griffon N, Bourdel MC, Sautel F, Sokoloff P, Schwartz JC, Ades J, Lôo H, Poirier MF (1998) Homozygosity at the dopamine D3 receptor gene is associated with opiate dependence. Mol Psychiatry 3, 333-336.
22. Dunbar J (1979) Issues in assessment. In: Cohen NSJ, ed. New Directions in Patient Compliance. New York: Lexington Books; 41-57.
23. Epstein LH, Temple JL, Neaderbiser BJ, Salis RJ, Erbe RW, Leddy JJ ( 2007) Food reinforcement, the dopamine D2 receptor genotype, and energy intake in obese and nonobese humans. Behav Neurosci 121, 877-886.
24. Fernstrom JD, Fernstrom MH.(2007) Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J Nutr 137(6 Suppl 1), 1539S-1547S
25. Kotler M, Cohen H, Segman R, Gritsenko I, Nemanov L, Lerer B, Kramer I, Zer-Zion M, Kletz I, Ebstein RP (1997) Excess dopamine D4 receptor (D4DR) exon III seven repeat allele in opioid-dependent subjects. Mol Psychiatry 2, 251-254.
26. Lawford BR, Young RM, Rowell JA, Qualichefski J, Fletcher BH, Syndulko K, Ritchie T, Noble EP (1995) Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele. Nat Med 1, 337-41.
27. Li T, Xu K, Deng H, Cai G, Liu J, Liu X, Wang R, Xiang X, Zhao J, Murray RM, Sham PC, Collier DA (1997) Association analysis of the dopamine D4 gene exon III VNTR and heroin abuse in Chinese subjects. Mol Psychiatry. 2, 413-416.
28. Liu W, Thielen RJ, Rodd ZA, McBride WJ (2006) Activation of serotonin-3 receptors increases dopamine release within the ventral tegmental area of Wistar and alcohol-preferring (P) rats. Alcohol 40, 167-176.
29. Males HH, Neale MC, Eaves IJ (1997) Genetic and environmental factors in relative body weight and human adiposity. Behav Genet 27, 325-351.
30. Marcello F, Grazia SM, Sergio M, Federigo S (1986) Pharmacological "enkephalinase" inhibition in man. Adv Exp Med Biol 198 Pt B, 153-160.
31. Maresh GA, Kastin AJ, Brown TT, Zadina JE, Banks WA (1999) Peptide transport system-1 (PTS-1) for Tyr-MIF-1 and Metenkephalin differs from the receptors for either. Brain Res 839, 336-40.
32. Meichenbaum D, Turk DC (1987) Facilitating Treatment Adherence: A Practitioner's Guidebook. New York: Plenum Publishing Corp.
33. Myers RD (1989) Isoquinolines, beta-carbolines and alcohol drinking: involvement of opioid and dopaminergic mechanisms. Experientia. 45, 436-443.
34. Noble EP (2003) D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet B Neuropsychiatr Genet 116,103-125
35. Sackett DL, Snow JC (1979) The magnitude of compliance and noncompliance. In: Haynes NRB, Taylor DW, Sackett DL, eds. Compliance in Healthcare. Baltimore: Johns Hopkins University Press; 11-22.
36. Tataranni PA, Baier L, Jenkinson C, Harper I, Del Parigi A, Bogardus CA (2001) Ser311Cys mutation in the human dopamine receptor D2 gene is associated with reduced energy expenditure. Diabetes 50, 901-904.
37. Thanos PK, Michaelides M, Umegaki H, Volkow ND (2008) D2R DNA transfer into the nucleus accumbens attenuates cocaine self-administration in rats. Synapse 62, 481-486.
38. Thanos PK, Rivera SN, Weaver K, Grandy DK, Rubinstein M, Umegaki H, Wang GJ, Hitzemann R, Volkow ND (2005) Dopamine D2R DNA transfer in dopamine D2 receptor-deficient mice: effects on ethanol drinking. Life Sci 77, 130-139.
39. Thanos PK, Volkow ND, Freimuth P, Umegaki H, Ikari H, Roth G, Ingram DK, Hitzemann R (2001) Overexpression of dopamine D2 receptors reduces alcohol self-administration. J Neurochem 78, 1094-1103.
40. Wang G-J, Volkow ND, Logan J, Pappers NR, Wong CT, Zhu W, Netusil. A ( 2001) Brain dopamine and obesity. Lancet 357, 354-357.
41. Wang GJ, Volkow, ND, Thanos PK, Fowler JS (2004) Similarity between obesity and drug addiction as assessed by neurofunctional imaging: a concept review. J Addict Dis 23, 39-53.
42. Xu K, Lichtermann D, Lipsky RH, Franke P, Liu X, Hu Y, Cao L, Schwab SG, Wildenauer DB, Bau CH, Ferro E, Astor W, Finch T, Terry J, Taubman J, Maier W, Goldman D (2004) Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations. Arch Gen Psychiatry. 61, 597-606.